Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin versus aspirin + ticagrelor for ex vivo infection-induced platelet activation in healthy volunteers
ACTRN12616001508460Phase 4Completed
- Sponsor
- Kathryn Hally
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of aspirin and ticagrelor in acute coronary syndrome (ACS) (2 arms), sponsored by Kathryn Hally. Primary endpoint: Platelet activation in response to synthetic infectious agents. Started Mar 2017; status: completed.
02
Drugs
aspirinticagrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ACTRN12616001508460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001508460.